323 related articles for article (PubMed ID: 19552963)
1. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
Canuso CM; Bossie CA; Turkoz I; Alphs L
Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
[TBL] [Abstract][Full Text] [Related]
3. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M
J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
12. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
[TBL] [Abstract][Full Text] [Related]
13. Paliperidone extended release: a review of its use in the management of schizophrenia.
Chwieduk CM; Keating GM
Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone extended release: in adolescents with schizophrenia.
Perry CM
Paediatr Drugs; 2012 Dec; 14(6):417-27. PubMed ID: 23050744
[TBL] [Abstract][Full Text] [Related]
15. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
18. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
20. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Sliwa JK; Bossie CA; Ma YW; Alphs L
Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
